The BRAF mutation is a rare mutation. It is only reported in about 3% to 5% of all NSCLC cases. It is found almost exclusively in the adenocarcinoma NSCLC subtype of lung cancer, but it occurs in ...
Intraoperative ultra-rapid droplet digital polymerase chain reaction (UR-ddPCR) can identify tumor genetic subtype and ...
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...
Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic ...
Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectivelyEnded 2024 with ...
Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...
A novel tool for rapidly identifying the genetic “fingerprints” of cancer cells may enable future surgeons to more accurately ...